LIMIT Early Adiposity Rebound in Children
LIMIT
LIMIT (LIfestyle and Microbiome InTeraction) Early Adiposity Rebound in Children
1 other identifier
observational
150
0 countries
N/A
Brief Summary
Childhood obesity is a strong predictor of adult obesity with health and economic consequences for the individual and society. Adiposity rebound (AR) is a rise in the Body Mass Index occurring between 3-7 years. Early adiposity rebound (EAR) occurs at a median age of 2 years and is a risk factor for later obesity. Events happening in "the first 1,000 days" play a role in obesity development. One of the key elements in this crucial time window is the gut microbiome, a highly dynamic organ that is sensitive to environmental exposure being linked to obesity development. Prenatal (dietary/lifestyle maternal factors and environmental exposure) and postnatal determinants (the type of feeding, sleep patterns, speed of growth) and environmental obesogenic pollutants may influence the infant microbial colonization, thus increasing the risk of EAR onset. LIMIT will holistically identify the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with AR vs EAR, driving new mechanistic insights to create an EAR predictive model. The study will evaluate a group of 150 mother-infant pairs, during the first four years of life at different follow-up.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Dec 2021
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 10, 2021
CompletedFirst Posted
Study publicly available on registry
July 14, 2021
CompletedStudy Start
First participant enrolled
December 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2026
ExpectedJuly 14, 2021
July 1, 2021
4.1 years
June 10, 2021
July 1, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Infant's intestinal microbiome assessment - relative abundance
To investigate the infant's intestinal microbiome development (0-48 months) by identifying the relative abundance of the dominant microbes.
0-48 month
Infant's intestinal microbiome assessment - microbial diversity
To investigate the infant's intestinal microbiome development (0-48 months) by assessing the microbial diversity.
0-48 month
Infant's intestinal microbiome assessment - inter-individual variation
To investigate the infant's intestinal microbiome development (0-48 months) by assessing the inter-individual variation.
0-48 month
Secondary Outcomes (11)
Adiposity rebound identification
0-48 month
Infant intestinal microbiome and pre-gestational weight status
0-48 month
Infant intestinal microbiome and maternal weight gain
0-48 month
Infant intestinal microbiome and maternal dietary habits
0-48 month
Infant intestinal microbiome and maternal physical activity
0-48 month
- +6 more secondary outcomes
Study Arms (1)
Dyads
Mother/infant pairs will be evaluated for anthropometric parameters, prenatal (dietary/lifestyle maternal factors)/postnatal determinants (type of feeding, sleep patterns, speed of growth) before discharge and after different follow-up after birth. Infant urinary and stool samples will be collected and stored. The infant adiposity rebound will be monitored.
Interventions
Identification of the longitudinal interplay between the intestinal microbiome and infant/maternal nutritional and lifestyle habits, environmental factors exposure and anthropometric measurements, in children with adiposity rebound vs children with early adiposity rebound.
Eligibility Criteria
Mother and infant pairs.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
* Infant stool samples for the gut microbiota analysis * Maternal blood samples for nutritional status evaluation. * Maternal urinary samples for endocrine disruptors chemicals. All biological samples will be collected and stored at -80°C until the analysis.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Rachele De Giuseppe, PhD
University of Pavia
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 10, 2021
First Posted
July 14, 2021
Study Start
December 1, 2021
Primary Completion
December 31, 2025
Study Completion (Estimated)
December 31, 2026
Last Updated
July 14, 2021
Record last verified: 2021-07
Data Sharing
- IPD Sharing
- Will not share